Samay
Overview
Samay is a pioneering company specializing in respiratory health, founded in 2018 by Dr. Maria Artunduaga. The company is headquartered in Mountain View, California, with an additional office in Medellín, Colombia. Samay focuses on developing AI-enabled acoustic resonance technology designed to assist in the management and prevention of respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD). As of November 2024, Samay has raised a total of $860K in funding from reputable organizations including MedTech Innovator and several venture investors.
Recent Developments
- November 2024: Samay was named one of Forbes’ 100 Startups to Watch in Colombia. This recognition underscores Samay's innovative approach and its mission to improve respiratory disease management.
- October 2024: Samay won the 2024 Early-Stage Grand Prize at the MedTech World Conference with the Sylvee device, receiving $350,000 in non-dilutive funding. The Sylvee device is noted for its advanced acoustic resonance technology, which assists in accurate COPD diagnosis and management.
- July 2024: The company secured a grant of $350,000 to further develop and test their proprietary COPD management technology.
- Early 2024: Samay participated in MedTech Innovator, and was the first Latin American-origin company to win the grand prize in the competition's 12-year history. The award brought additional spotlight to the company's efforts and the broader Latino medtech landscape.
- November 2023: Samay was involved in a significant feasibility trial, providing crucial data that is expected to support further grant applications and clinical testing phases.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2018 |
| Headquarters | Mountain View, CA |
| Founders | Dr. Maria Artunduaga |
| Revenue | Not disclosed |
| Profits | Not disclosed |
| Key Investors | MedTech Innovator, Alamo Angels, E14 Fund |
| Industry | Monitoring Equipment |
| Number of Employees | 2-10 |
Early History
Samay was founded in 2018 by Dr. Maria Artunduaga, an accomplished medical professional with a personal vested interest in respiratory health. The inception of Samay was driven by Dr. Artunduaga's determination to improve early diagnosis and management of COPD and other respiratory diseases, inspired by the loss of her grandmother to the illness. The company's initial focus was on utilizing AI and machine learning to develop a wearable technology that could non-invasively monitor lung health, aiming to predict exacerbations well in advance.
Company Profile and Achievements
Samay is a private company focusing on the healthcare sector, specifically on respiratory disease management. The company developed an AI-driven device, Sylvee, which is pivotal in the early detection and management of COPD. Key achievements include:
- 2024 MedTech Innovator Grand Prize: Winning this prestigious award was a significant milestone, recognizing their groundbreaking work in developing the Sylvee device.
- Clinical Impact: Samay's technology provides a much-needed solution for monitoring pulmonary health, significantly improving patient management at home and potentially reducing hospital visitations.
- Innovative Approach: Samay's patented acoustic resonance technology represents a leap forward in using AI for healthcare, showing promise in global COPD management and diagnostics.
Current Operations and Market Position
Currently, Samay focuses on expanding its market presence within North and South America. Leveraging their cutting-edge technology, Samay aims to fill a critical gap in respiratory health management. By integrating low-cost, easily accessible technology with powerful diagnostics, the company positions itself as a cost-effective solution for widespread respiratory monitoring. Samay's competitive advantage lies in its proprietary AI technology that offers more precise diagnostics, helping it stand out in a crowded medtech market.
Conclusion
Samay stands at the forefront of innovation in the respiratory health industry. Its commitment to utilizing artificial intelligence to improve the quality and accessibility of care for respiratory diseases positions it as a vital player in global healthcare. With the prestigious MedTech Innovator Grand Prize win underscoring its innovative capacity, Samay is poised for significant growth, with future opportunities likely to arise in international markets in need of effective COPD management solutions.